Abstract
Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.
Cite
CITATION STYLE
APA
Openshaw, M. R., Pinato, D. J., & Valeri, N. (2021). Back from the brink: EGFR inhibition in gastroesophageal cancer. Clinical Cancer Research, 27(11), 2964–2966. https://doi.org/10.1158/1078-0432.CCR-21-0533
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free